OTTAWA, ONTARIO--(MARKET WIRE)--Sep 12, 2007 -- Chemaphor Inc. (CDNX:CFR.V - News), a biotechnology research and development company, announced today that it has received proceeds from its collaborative research, license and commercialization agreement with Elanco Animal Health (“Elanco”), a division of Eli Lilly and Company (NYSE:LLY - News) to license its OxBC product technology (“OxBC”). The agreement establishes the framework for Chemaphor and Elanco to research, develop and potentially commercialize products for use in poultry and other food animal species using OxBC technology. The Company expects to recognize the proceeds as revenue as the services are delivered.
